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Abstract: 
Background: MDMA therapy has qualities that make it potentially well-suited for patients 
with addictions (Sessa 2017), but this has never been explored in a research study. We present 
data from the Bristol-Imperial-MDMA-for-Alcoholism (BIMA) study. This is the first MDMA 
addictions study; an open-label safety and tolerability proof-of-concept study investigating the 
potential role for MDMA therapy in treating patients with Alcohol Use Disorder (AUD). 
Aims: To assess if MDMA-Assisted Psychotherapy can be delivered safely and can be 
tolerated by patients with AUD post-detoxification. Outcomes regarding drinking behaviour, 
quality of life and psychosocial functioning were evaluated. 
Methods: 14 patients with AUD completed a community alcohol detoxification and received 
an 8-week course of recovery-based therapy. Participants received two sessions with MDMA 
(187.5mg each session). Psychological support was provided before, during and after each 
session. Safety and tolerability were assessed alongside psychological and physiological 
outcome measures. Alcohol use behaviour, mental wellbeing and functioning data were 




Results: MDMA treatment was well-tolerated by all participants. No unexpected adverse 
events were observed. Psychosocial functioning improved across the cohort. Regarding alcohol 
use, at 9-months post-detox the average units of alcohol consumption by participants was 18.7 
units/week, compared with 130.6 unit/week pre-detox. This compares favourably to a previous 
observational study (the ‘Outcomes’ study) by the same team with a similar population of 
people with AUD (Sessa et al 2020). 
Conclusions: This study provides preliminary support for the safety and tolerability of a novel 
intervention for AUD post-detox. Further trials to better examine the therapeutic potential of 











Alcohol Use Disorder: Drinking is a socially acceptable behaviour and the majority of people 
consume alcohol without significant problems, but a growing number drink in a harmful 
manner. Alcohol Use Disorder (AUD), (DSM-5, APA 2013) encompasses a broad spectrum of 
clinical presentations related to harm associated with alcohol use. Approximately 24% of the 
adult population of England consume alcohol harmfully, with about 6% of men and 2% of 
women meeting criteria for alcohol physical dependence. AUD is characterised by often 
serious withdrawal symptoms on cessation of alcohol, drinking to avoid withdrawal symptoms, 
tolerance, the persistent desire to drink and continuing drinking despite negative consequences 
(NICE guidelines on Alcohol Use Disorders, 2011). The impact of alcohol misuse is 
widespread; encompassing alcohol-related illness and injuries as well as significant social 
impacts to family, friends and the wider community. Patients with AUD frequently have a past 
history of psychological trauma and commonly present with high levels of depression, social 
anxiety and social exclusion, having become dependent upon alcohol as a form of self-
medication (Castillo-Carniglia et al 2019). And in the context of the current Covid 19 
pandemic, attention to the issue of best management of AUD has become even more pertinent 
(Clay & Parker 2020). 
Traditional treatments for AUD include medical and psychosocial interventions. 
Pharmacological options include acamprosate, naltrexone, nalmefene and disulfiram, which 
reduce cravings and deter relapse respectively (Rösner et al 2010, Soyka & Rösner 2008, Paille 
& Martini 2014, Krampe et al 2006). Benzodiazepines are commonly prescribed as part of 
alcohol detoxification programmes (Lingford-Hughes et al 2012). Large-scale studies of 
psychosocial interventions have emphasised the importance of psychotherapies and non-




1997a, Anton et al., 2006, UKATT Research Team 2005). In recent years, Mindfulness 
techniques have been increasingly explored as a potential approach to assist recovery through 
interrupting the tendency to respond to stress with alcohol use and not to react automatically to 
cravings (Marcus and Zgierska 2009).  
MDMA:  MDMA is a phenethylamine that raises levels of monoamine neurotransmitters in 
the brain. MDMA elevates mood, increases sociability and feelings of closeness to others, and 
can facilitate imagination and memory (Sessa, Higbed & Nutt 2019). Evidence from 
neuroimaging studies show a decrease in amygdala/hippocampus activity (Carhart-Harris et al 
(2014) and an association between reduced amygdala activity and improved ability to process 
negative memories. (Carhart-Harris et al 2013). Together with changes in social cognition, 
interpersonal closeness and communication, these data support the proposition that MDMA 
could be of benefit as an adjunctive psychotherapeutic treatment for alcohol addiction and 
comorbid psychological disorders (Sessa 2017).  The use of MDMA-assisted psychotherapy to 
manage PTSD has been explored since the 1980s (Greer 1998). More recently, long term 
follow-up data from the first completed trial of MDMA-assisted psychotherapy for chronic, 
treatment-resistant PTSD has found statistically and clinically- significant gains in symptom 
relief with no subjects reporting harm from participation in the study (Mithoefer et al 2010; 
Mithoefer et al 2013). The US-based research group, the Multidisciplinary Association for 
Psychedelic Studies (MAPS), have published favourable results of their phase 2 studies 
(Mithoefer et al 2019). MAPS is now in the Phase 3 stage of medicine development, with 
anticipated licensing and FDA approval in the USA in late 2022 to early 2023. European 
approval by EMA is anticipated in 2023. 
The potential risks associated with MDMA as an adjunct to psychotherapy: Rarely, users 




experiences (Mithoefer et al 2010). Acute neurocognitive effects include a transient reduction 
in verbal and visual memory, which tend to resolve after the drug has worn off (Kuypers 2007). 
MDMA misuse potential needs to be borne in mind when proposing giving the drug to a 
population with pre-existing addiction issues. However, in the studies in which MDMA has 
been administered clinically in a therapeutic setting to healthy volunteers without any previous 
experience with ecstasy, subjects did not express a wish to use it outside of the clinical setting 
(Mithoefer 2013). Taken together, these findings suggest that clinically administered MDMA 
is not likely to produce problematic use (Jerome et al 2013). In order to monitor the risk of 
patients using MDMA outside of the study, we monitored their use or desire to use illicit 
ecstasy with specific questions pertaining to this issue asked in the final (session 10) therapy 
session.  
Clinical MDMA increases blood pressure, heart rate and body temperature (Harris et al 2002) 
and causes jaw tightness, bruxism, reduced appetite, poor concentration and impaired balance 
(Mithoefer 2010). Despite historical reports of neurocognitive deficits in recreational ecstasy 
users, contemporary studies have failed to demonstrate any significant long-term neurotoxicity 
associated with recreational ecstasy when use of other recreational drugs is controlled for 
(Hanson & Luciana, 2010, Selvaraj 2009). There have been no reports of long-term 
neurotoxicity or neurocognitive impairments when pure MDMA has been administered in a 
controlled clinical setting (Mithoefer 2013).  
Methods   
Approvals and drug source: This trial, sponsored and approved by Imperial College London, 
received a favourable opinion from the Central Bristol Research Ethics Committee of the 
National Research Ethics Service and from the Medicines and Healthcare products Regulatory 




obtained.  GMP MDMA was obtained from Sterling Pharmaceuticals (Newcastle) and 
formulated into the investigational medicinal product (62.5mg MDMA in gelatine capsules) by 
Guy’s and St Thomas’ Hospital’s Pharmacy Manufacturing Unit (London, UK).     
Study design: This was an open label within-subject safety and tolerability feasibility study, 
in 14 patients aged 18 to 65 with AUD who had recently undergone detoxification. All patients 
received MDMA-Assisted therapy. The main outcome measures were the number of patients 
completing the 8-week psychotherapy course, the number accepting the second booster dose 
of MDMA on drug assisted days and adverse events. Secondary outcome measures included 
changes in drinking behaviour (measured by ‘units per week consumed’ at 3-, 6- and 9-months 
since completion of  detoxification), measures of mental wellbeing, psycho-social functioning, 
quality of life and concomitant drug use.  
Patients with a primary diagnosis of AUD who were seeking detoxification – with or without 
medical assistance - were recruited from the North Somerset Substance Misuse Service 
(‘Addaction’). Patients received an eight-week course of recovery-based therapy comprising 
10 psychotherapy sessions. On two of these (session 3 and session 7) patients were dosed with 
open-label MDMA during a 6-8 hour assisted therapy session. On each dosing session, 
participants received an initial oral dose of 125mg MDMA, followed two-hours later by a 
booster dose of 62.5mg MDMA. The booster dose served to prolong the experience, allowing 
for greater time for psychotherapy under the influence of the drug.  
Other sessions (1, 2, 4, 5, 6, 8-10) comprised 1-hour psychotherapy sessions, employing aspects 
of Motivational Interviewing and ‘third wave’ cognitive-behavioural approaches. Patients 





The inclusion and exclusion criteria were as follows: 
Inclusion Criteria 
• Informed consent 
• Primary diagnosis (as defined by DSM-5) of alcohol use disorder.  
• Successful alcohol detoxification (no longer consuming any alcoholic substances). 
• Between 18 and 65 years old. 
• Be able to identify in advance a supportive significant other(s) who could accompany the 
patient to study visits if required and be contacted by the study team in the event that the 
patient themselves cannot be contacted.  
• Proficient in speaking and reading English.  
• Agree to comply with requirements of protocol. 
 
Exclusion Criteria 
• Lacking capacity 
• History of, or a current, primary psychotic disorder, bipolar affective disorder type 1 or 
personality disorder.  
• Present a serious suicide risk; as determined by the Columbia-Suicide Severity Risk Scale 
(C-SSRS).  
• Relevant abnormal clinical findings at screening visit judged by the investigator to render 
subject unsuitable for study. Including but not limited to a history of cardiac disease, 
hypertension and stroke, severe liver disease, history of epilepsy, istory of Malignant 
Hyperthermia (Central Core Disease) 
• Regular user of Ecstasy (material represented as containing MDMA). E.g. more than five 




• Currently taking or unwilling/unable to stop any medications likely to interact with MDMA 
the opinion of the investigators, during 8 week MDMA assisted therapy. 
• Regular use of/dependence on other drugs such as benzodiazepines, synthetic 
cannabinoids, cocaine and heroin. 
• For females of childbearing age/potential, articipants must use an effective form of birth 
control for at least six days after administration of MDMA, and must not be pregnant and/or 
breast-feeding, until the end of the treatment phase. 
• For males with partners of childbearing age/potential, participants must themselves confirm 
use of an effective form of birth control for at least six days after administration of MDMA 
and confirm their partner will also. 
• Taken part in a study involving an investigational product in the last three months 
• Patients that might face additional risks from immunosuppression (for example patients 
with immunological diseases, patients with active infection or history of infections within 
4 weeks of MDMA administration). 
AUD was identified using the DSM-IV SCID interview. Screening comprised of written 
informed consent, an evaluation of the patient’s physical and mental health background, a 
psychiatric interview (MINI), assessments of depression and anxiety severity were assessed 
using the PHQ-9 and GAD-7 questionnaires. Severity of AUD was established using the SADQ 
and SIP questionnaires.  Patients received a thorough physical health check comprising of an 
electrocardiogram (ECG), routine blood tests, blood pressure, heart rate, and physical 
examination. Following screening, eligible patients underwent the process of detoxification; 
either by gradually cutting down alcohol consumption over many weeks, or with a medically-
assisted detoxification regime. The majority of participants were also taking medications for 




associated medications that are known to attenuate the effects of MDMA were subsequently 
gradually reduced and stopped under medical supervision, ahead of the first MDMA session. 
A further ‘baseline’ visit clarified successful detoxification using the CIWA questionnaire 
before eligible participants entered the 8-week course of psychotherapy. This entailed weekly 
60-minute outpatient non-drug psychotherapy sessions, delivered by two clinicians (BS and 
LH), trained in delivering MDMA-assisted psychotherapy by the USA based organisation, 
MAPS. 
Dosing with MDMA occurred twice during the 8-week course; on weeks 3 and 6. Physiological 
changes, observer and subject ratings of distress (SUDS) and the intensity of MDMA’s acute 
psychoactive effects were measured throughout the drug-assisted session. Acute anxiety was 
managed primarily psychologically, but sedative medication (oral lorazepam) was available. 
Participants remained overnight in the treatment centre after each drug-assisted session, 
overseen by medically-trained ‘night sitters’, on hand to support participants as required but 
instructed to avoid delivering any psychotherapeutic interventions. 
Participants were seen the morning after each drug-assisted session for an integration 
psychotherapy session, and then telephoned daily for six days to assess changes to mood, 
suicidal risk factors (using C-SSRS) and quality of sleep (using the Leeds Sleep questionnaire). 
Following the end of the 8-week therapeutic course participants carried out additional follow-
up questionnaires. They were then seen again at 3-, 6- and 9-months (since baseline) for longer-
term follow-up data collection. 
 
Data analysis 
All data were recorded on paper CRF’s and then digitized into MS Excel spreadsheets. Analysis 
and graphing were performed using GraphPad (Prism) or MS Excel. As this is a non-RTC, 




Back results, alcohol consumption levels at last observation were used in the case of drop-outs 




• 36 participants attended face-to-face screening visits.  
• 14 were enrolled; 8 males and 6 females; average age 48 years.  
• All were White British.  
• 4 were employed, 9 unemployed and 1 was retired.  
• The average age of first alcohol use was 13 years-old.  
• The average age when alcohol became problematic was 34 years-old.  
• 64% of participants reported a history of alcohol-related blackouts, 14% had 
experienced alcohol withdrawal-induced seizures, 86% of participants reported having 
experienced risky or vulnerable incidences due to alcohol and 75% of participants had 
had forensic / offending behaviour secondary to their alcohol use.  
 
Severity of AUD criteria at screening and baseline: As per the inclusion criteria, all eligible 
patients scored above the diagnostic threshold on the DSM-5 SCID questionnaire for AUD. 
We also measured AUD severity using the SIP questionnaire and the SADQ questionnaire 
(figure 1), with most eligible participants in the moderate to severe range. At the point of 
Baseline visit, (within one week of detox completion), 100% of eligible participants had 





Figure 1. Severity of Alcohol Questionnaire (SADQ) measures alcohol dependency (Au = arbitrary units). Short 
Inventory of Problems for Alcohol (SIP) is a 15-question measure of self-noted consequences of drinking. Both 
observed at screening. SIP categories are separated each between 0-100% on the second y-axis. A score of 31 or 
higher indicates severe alcohol use disorder severity, a score of 16-30 indicates moderate alcohol use disorder 
severity (light grey area), anything lower than 16 indicates mild alcohol use disorder severity (dark grey area). 4 
SADQ questions were unanswered, in which case, mean substitution was applied using the average row value for 
the relevant time period and participant. B05, B16, B20 and B21 had one question missing each. 
 
Physiological and Tolerability Effects during MDMA sessions: Twelve of the fourteen 
participants received both sessions of MDMA-assisted psychotherapy. So, in  total, 26 drug-
assisted psychotherapy sessions with MDMA were administered during the trial. Temperature, 
blood pressure and heart rate were measured at t=0, before taking the medicine, then half-
hourly up to t=2 hours, then hourly thereafter for a minimum of 6-hours from the time of dosing 
(figure 2).  
Except for one participant, all of these physiological parameters remained within normal limits 
for all these sessions. As expected, we saw a mild, transient rise on blood pressure, temperature 
and heart rate over the course of the MDMA session. No patients experienced sustained 
abnormal physiological disturbance, symptomatic experiences of raised blood pressure, heart 
rate or temperature or any other adverse events during MDMA sessions. No medical 




sessions.  One participant experienced a transient abnormal rise in blood pressure after taking 
the initial dose of 125mg MDMA reaching a BP 183/118 at 2-hours after dosing, attributed to 
the participant forgetting to take her regular antihypertensive medication on the morning of 
dosing. Although she was asymptomatic and no medical intervention was required it was 
decided to withhold the 2-hour supplemental dose. Her blood pressure subsequently 
spontaneously returned to normal in the following two hours and she agreed with the study 
team to omit the booster dose of MDMA on that day. She did, however, receive her second 
MDMA session three weeks later, (after taking her antihypertensive medication in advance 
appropriately), which was uneventful in terms of blood pressure. Another participant only 
received  their first session with MDMA. She subsequently relapsed back to heavy drinking in 
the context of personal psychosocial issues unconnected with the study, and therefore chose to 
not have her second MDMA session.  
Subjective Units of Distress (SUDS) and Participant report of Drug Effects were also 
measured, hourly, throughout the MDMA sessions (figure 3). Most subjects predictably 
reported mildly raised SUDS scores at the beginning of the sessions before taking MDMA – 
consistent with expected anxiety ahead of dosing – which subsequently reduced during the 
course of the session as the positive effects of MDMA emerged. Participants gave their own 
subjective score (0-10) of whether they felt Drug Effects, and the therapists also recorded their 
own objective score of how ‘altered’ the participant appeared. There was no significant 
difference between Observers’ and Participants’ Drug Effects scores. Drug Effects rose 
expectedly over the first 2-hours, with a notable further increase after the booster dose was 
given at t=2 hours, and a subsequent plateau then decline over the following six hours. By the 
end of the MDMA session day all drug effects had returned to baseline. No participants 
reported any significant neurocognitive impairments associated with receiving MDMA in the 





Figure 2. Pooled data of Blood Pressure, Temperature, Heart Rate, Observed Drug Effects and Subjective Units 
of Distress (SUDS) observed over the duration of the MDMA sessions. SUDS and Drug Effects observed over 8 
hours, physiological data observed over 6 hours following dosing. Mean data for each session is used, except in 
the case of missing data, where available session data is applied. Error bars (where applied) indicate +/- SEM. 
 
Changes in Drinking Behaviour: Whilst changes in drinking behaviour were not a primary 
outcome measure, we nevertheless collected data in respect of Units of Alcohol Consumed per 
Week in the month before participants’ detoxification, immediately after detox (‘Baseline’), 
throughout the 8-week MDMA therapy course and for up to 9-months after detox. Of the n=14 
eligible participants who underwent the course of MDMA-assisted psychotherapy, at nine-
months follow-up endpoint, 11 participants were drinking less than 14 units of alcohol/week 




drinking over 14 units of alcohol/week. On average participants were drinking 130.6 units of 
alcohol / week in the month before detoxification, zero at the point of detox, and at the end of 
9-months the average amount of consumed alcohol had risen back to 18.7 units / week (figure 
3). 
 
Figure 3. Timeline Follow Back (TLFB), assesses drinking behaviour prior to, and following the study. Data is 
collected daily by self-reporting and reviewed at 1 month prior to detox, immediately following detox and at 1, 3, 
6, and 9 months follow-up. A full dataset was not available for 3 of the participants. One participant dropped out 
of the study at 3-months and two patients failed to provide data at 9-month follow-up. Two participants had a 
second detoxes since starting the study. For these participants, TLFB drinking behaviour data was carried forward 
from the point of drinking levels pre-second detox.   
 
Seven-Day Follow-Up after MDMA sessions: Considerable medical and popular press 
literature reports the anecdotal observation of ecstasy users experiencing an acute ‘come down’ 
effect and a drop in mood in the days after using the drug recreationally. In order to measure 
this prospectively with clinical MDMA, we measured participants’ mood states by daily Profile 
Of Mood States (POMS) measurements for 7-days after each MDMA session. (figure 4). 




below zero represent a positively felt mood. Average scores across both MDMA sessions for 
all 14 participants (26 MDMA sessions) reveal no evidence of any mood disturbance during 
the week after taking each session of clinical MDMA. Indeed, participants sustained a positive 
mood for 7-days. This result contrasts with anecdotal reports from recreational ecstasy users.  
 
Figure 4. Profile of Mood States (POMS), individual composite scores of mood disturbance observed daily over 
a week following dosing. Mean data shown for both MDMA sessions. In the case of absent data for either 
session the available data for the remaining session is used. 
 
 
Other Mental Health Measures and Quality of life measures: Brief assessments of mood 
and anxiety were made at screening, baseline, after the 8-week MDMA Therapy course and at 
3,6 and 9-month follow-ups, using the PHQ-9 and GAD-7 rating scales respectively (figure 5). 
Scores demonstrate a reduction in both anxiety and depression after screening and baseline 
timepoints, followed by a transient rise in anxiety and depression scores 3-months after 





Figure 5. General Anxiety Disorder 7 (GAD-7) and Patient Health Questionnaire 9 (PHQ-9). Self-report scales 
for anxiety and depression (respectively). Recorded at screening, baseline, week 10, then 3, 6, and 9 months 
follow-up. Greater scores report indication of heightened anxiety/depression. Error bars indicate +/- SEM. 
 
Suicidality: Participants underwent the C-SSRS rating scale at screening, baseline, throughout 
the 8-week therapy course, in the week after each MDMA session and at 3-, 6- and 9-month 
follow-up visits. No participants reported current suicidal ideation, intent or plans or self-harm 
behaviour during the course of the study 
Adverse Events: The acute effects of MDMA-assisted psychotherapy were well-tolerated by 
participants. No unexpected adverse events occurred. No participants reported any desire to 
use illicit ecstasy / illicit MDMA following receiving clinical MDMA as part of this trial. No 
psychotic symptoms were observed in any of the patients. 
A variety of further data were collected, including changes to the quality of sleep, quality of 
life measures and changes to compassion and empathy scales, which will be published in 
forthcoming papers.  
 
Discussion 
In this first safety and tolerability study, we demonstrate that MDMA-assisted psychotherapy 




psychotherapeutic process or indirectly through augmenting the treatment of co-morbid 
psychological conditions commonly associated with alcohol use disorder (Jerome et al 2013).  
The capacity for MDMA to increase feelings of empathy and compassion for the self and others 
may contribute to improved self-awareness and subsequently reduce the denial of harmful use 
of alcohol. Recreational MDMA users have reported improved intrapersonal attitudes and pro- 
social attitudes towards the self, which could be a mechanism by which the drug enhances 
psychotherapy, especially for patients with pre-existing histories of trauma (Stolaroff 2004). 
Similarly, Mithoefer (2010) described MDMA’s capacity to "make yourself present in the 
moment"; a core concept of mindfulness. Drug-assisted psychotherapies with the ‘classic’ 
psychedelic compounds LSD and psilocybin utilise the induced subjective mystical / spiritual 
effects of the psychedelic experience and have found the depth of this experience is strongly 
associated with maintained recovery from harmful substance use (Sessa & Johnson 2015). 
However, not all patients are able or willing to tolerate the classic psychedelic experience, and 
compliance is a critical aspect of addiction therapy. Whilst there is also an, albeit minimal, 
subjective spiritual / mystical experience associated with MDMA (Sumnall et al, 2006), it is 
generally better tolerated than the classic psychedelics, with less perceptually disturbing effects 
compared to LSD and psilocybin. Therefore, MDMA offers an alternative opportunity for 
enhanced psychotherapy in patients with AUD.  
Prior to carrying out the BIMA study, the same study team carried out a non-interventional 
observational study, following n=14 participants through their treatment-as-usual post-alcohol 
detox (the ‘Outcomes Study’) (Sessa et al 2020). The eligibility criteria and questionnaires used 
in the Outcomes Study were similar to the BIMA study, in respect of assessment of AUD, 
severity of AUD, success of detoxification and follow-up of outcomes in respect of mental 




the additional 8-week therapeutic course with MDMA-assisted psychotherapy, which occurred 
post-detox. Whilst it is not appropriate to statistically compare these two studies – as patients 
were not randomised into the studies - the graph below demonstrates the success of BIMA 
participants in terms of alcohol consumption over 9 months, compared with current best 
treatments available locally.  Only 21% of participants who had undergone MDMA-assisted 
psychotherapy were drinking in excess of 14 units of alcohol a week in comparison with the 
75% observed in the Outcomes Study (figure 6). 
 
Figure 6. TLFB showing % of patients consuming more than the 14 recommended daily units of alcohol (Sessa 
et al 2020). 
 
 
Limitations: The BIMA study had a relatively small sample size. As directed by the 
Medicines and Healthcare products Regulatory Agency (MHRA), given that the study was 




an open-label, non-placebo-controlled study. Therefore all patients knew they would be 
getting MDMA. Whilst efforts were made to test objectively for alcohol use using regular 
breath alcohol analysis, review of participants’ medical notes throughout the study and 
carrying out Gamma-GT blood tests post-course, all data represented above were nonetheless 
reliant primarily on retrospective self-report. The study team considered other techniques to 
objectively assess alcohol use, such as worn alcohol sweat meters, but given that efficacy 
(drinking outcome) was not a primary outcome measure this was concluded to be overly 
intrusive for this type of study.  
Conclusion: 
In summary, this study demonstrates that MDMA-assisted psychotherapy can be safely 
delivered, is well tolerated and has the potential to enhance and intensify the psychotherapeutic 
processes in the treatment of patients with AUD. MDMA, given in a psychotherapeutic context, 
may reduce avoidance of emotionally distressing thoughts, images or memories of alcohol 
misuse while increasing empathy for the self and others. It may also address symptoms of other 
conditions that are frequently comorbid with harmful use of substances, particularly those 
symptoms associated with a history of psychological trauma.  
A logical next-step would be to carry out a placebo-controlled RCT in which the level of 
therapist-contact is consistent between conditions. This would enable any between-group 
differences in clinical outcomes to be attributed to MDMA rather than the psychological 
support provided.  
 




Research in context: Evidence before this study: The database Pubmed was searched up 
until the 30th April 2016, using the terms “MDMA”, “alcohol use disorder”, “alcoholism” and 
“addictions”. We did not find any clinical trials assessing MDMA as a treatment for alcohol 
use disorder – or any other substance use addiction. We found just one editorial proposing the 
theoretical potential for MDMA-assisted psychotherapy in the treatment of addictions (Jerome 
et al 2013). There have been scant animal studies on the subject. In one study, two strains of 
rats who had been previously conditioned to show a preference for alcohol showed an 
attenuation of alcohol use after administration with MDMA (Rezvani 1992). 
Added value of this research: To our knowledge, this is the first investigation of the safety 
and tolerability of MDMA-assisted psychotherapy as a treatment for AUD. Our findings 
demonstrate that MDMA-assisted psychotherapy is feasible, safe and may have value as a 
treatment option in the management of AUD. Both sessions of MDMA-assisted psychotherapy, 
with doses of 187.5mg (in split doses each session) were well-tolerated and led to enduring 
reductions in symptom severity, sustained for 9-months in the majority of participants.   
Implications of all the available evidence: The results of this small-scale safety and 
tolerability study should help motivate further research into the efficacy of MDMA-assisted 
psychotherapy with psychological support for alcohol use disorder. Larger-scale RCTs are 
warranted to better examine the potential of MDMA-assisted psychotherapy as a treatment 
option for this highly prevalent, disabling, costly and difficult to treat disorder. More broadly, 
the present study should help to catalyse the re-emergence of MDMA facilitated psychotherapy 
as a promising mental health research area.  
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